keyword
https://read.qxmd.com/read/38163382/longitudinal-changes-in-clinical-symptoms-and-proposed-biomarkers-for-prodromal-dementia-with-lewy-bodies-in-an-older-patient-with-depression
#21
JOURNAL ARTICLE
Daichi Morioka, Ryota Kobayashi, Shinobu Kawakatsu, Kazutaka Sakamoto, Akihito Suzuki
No abstract text is available yet for this article.
January 1, 2024: Psychogeriatrics: the Official Journal of the Japanese Psychogeriatric Society
https://read.qxmd.com/read/38105206/pathological-correlates-of-cognitive-decline-in-parkinson-s-disease-from-molecules-to-neural-networks
#22
REVIEW
Nikolai I Novikov, Elena S Brazhnik, Valentina F Kitchigina
Parkinson's disease (PD) is a progressive neurodegenerative disorder caused by the death of dopaminergic neurons in the substantia nigra and appearance of protein aggregates (Lewy bodies) consisting predominantly of α-synuclein in neurons. PD is currently recognized as a multisystem disorder characterized by severe motor impairments and various non-motor symptoms. Cognitive decline is one of the most common and worrisome non-motor symptoms. Moderate cognitive impairments (CI) are diagnosed already at the early stages of PD, usually transform into dementia...
November 2023: Biochemistry. Biokhimii︠a︡
https://read.qxmd.com/read/38094003/potential-neural-substrates-underlying-circadian-and-olfactory-disruptions-in-preclinical-alzheimer-s-disease
#23
REVIEW
Quiana L Jeffs, Jonathan F Prather, William D Todd
Alzheimer's disease (AD) is the leading cause of dementia, with over 45 million patients worldwide, and poses significant economic and emotional burdens to both patients and caregivers, significantly raising the number of those affected. Unfortunately, much of the existing research on the disease only addresses a small subset of associated symptomologies and pathologies. In this review, we propose to target the earliest stages of the disease, when symptomology first arises. In these stages, before the onset of hallmark symptoms of AD such as cognitive impairments and memory loss, circadian and olfactory disruptions arise and are detectable...
2023: Frontiers in Neuroscience
https://read.qxmd.com/read/38069360/pathogenic-impact-of-fatty-acid-binding-proteins-in-parkinson-s-disease-potential-biomarkers-and-therapeutic-targets
#24
REVIEW
Ichiro Kawahata, Kohji Fukunaga
Parkinson's disease is a neurodegenerative condition characterized by motor dysfunction resulting from the degeneration of dopamine-producing neurons in the midbrain. This dopamine deficiency gives rise to a spectrum of movement-related symptoms, including tremors, rigidity, and bradykinesia. While the precise etiology of Parkinson's disease remains elusive, genetic mutations, protein aggregation, inflammatory processes, and oxidative stress are believed to contribute to its development. In this context, fatty acid-binding proteins (FABPs) in the central nervous system, FABP3, FABP5, and FABP7, impact α-synuclein aggregation, neurotoxicity, and neuroinflammation...
December 1, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/38067664/research-progress-on-effects-of-ginsenoside-rg2-and-rh1-on-nervous-system-and-related-mechanisms
#25
REVIEW
Silu Liu, Weijia Chen, Yan Zhao, Ying Zong, Jianming Li, Zhongmei He
Neurological-related disorders are diseases that affect the body's neurons or peripheral nerve tissue, such as Parkinson's disease (PD) and Alzheimer's disease (AD). The development of neurological disorders can cause serious harm to the quality of life and functioning of the patient. The use of traditional therapeutic agents such as dopamine-promoting drugs, anticholinergic drugs, cholinesterase inhibitors, and NMDA receptor antagonists is often accompanied by a series of side effects such as drug resistance, cardiac arrhythmia, liver function abnormalities, and blurred vision...
December 4, 2023: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://read.qxmd.com/read/38049965/behavioral-variant-frontotemporal-dementia-with-the-dominantly-affected-caudate-nucleus-in-18f-fp-cit-pet-ct
#26
JOURNAL ARTICLE
Yeongjoo Lee, Seonjeong Byun, Sae Jung Na
Frontotemporal dementia is a clinical syndrome that is characterized by a progressive deterioration in behavior, personality, and/or language, with relative preservation of memory, and its phenotype and molecular basis are heterogeneous. We present a case of a 62-year-old female patient who underwent 18F-FDG PET/CT and 18F-FP-CIT PET/CT for differential diagnosis of psychiatric disease and types of dementia. 18F-FDG PET/CT image showed a compatible finding for frontotemporal dementia, and 18F-FP-CIT PET/CT image showed dominantly decreased dopamine transporter activity in the bilateral caudate nucleus...
December 5, 2023: Clinical Nuclear Medicine
https://read.qxmd.com/read/38048087/neuronally-derived-extracellular-vesicle-%C3%AE-synuclein-as-a-serum-biomarker-for-individuals-at-risk-of-developing-parkinson-disease
#27
JOURNAL ARTICLE
Shijun Yan, Cheng Jiang, Annette Janzen, Thomas R Barber, Aline Seger, Michael Sommerauer, Jason J Davis, Kenneth Marek, Michele T Hu, Wolfgang H Oertel, George K Tofaris
IMPORTANCE: Nonmotor symptoms of Parkinson disease (PD) often predate the movement disorder by decades. Currently, there is no blood biomarker to define this prodromal phase. OBJECTIVE: To investigate whether α-synuclein in neuronally derived serum-extracellular vesicles identifies individuals at risk of developing PD and related dementia. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, cross-sectional multicenter study of serum samples included the Oxford Discovery, Marburg, Cologne, and Parkinson's Progression Markers Initiative cohorts...
December 4, 2023: JAMA Neurology
https://read.qxmd.com/read/37992545/dopamine-transporter-positron-emission-tomography-in-patients-with-alzheimer-s-disease-with-lewy-body-disease-features
#28
JOURNAL ARTICLE
Sungwoo Kang, Seun Jeon, Young-Gun Lee, Byoung Seok Ye
In 36 normal controls (NC), 37 patients with Alzheimer's disease (AD) without parkinsonism (ADP- ), 31 AD with parkinsonism (ADP+ ), and 40 AD with dementia with Lewy bodies (ADDLB ), dual-phase dopamine transporter (DAT) positron emission tomography (PET) were performed to evaluate the diagnostic performance of DAT and early-to-delayed uptake ratios (E/Ds) in the anterior caudate (AC), posterior caudate (PC), anterior putamen (AP), posterior putamen (PP), and substantia nigra (SN) to differentiate ADP+ /ADDLB from NC, and their effects on parkinsonism and cognition...
October 21, 2023: Neurobiology of Aging
https://read.qxmd.com/read/37971501/metabolic-network-alterations-as-a-supportive-biomarker-in-dementia-with-lewy-bodies-with-preserved-dopamine-transmission
#29
JOURNAL ARTICLE
Anna Stockbauer, Leonie Beyer, Maria Huber, Annika Kreuzer, Carla Palleis, Sabrina Katzdobler, Boris-Stephan Rauchmann, Silvia Morbelli, Andrea Chincarini, Rose Bruffaerts, Rik Vandenberghe, Milica G Kramberger, Maja Trost, Valentina Garibotto, Nicolas Nicastro, Aurélien Lathuilière, Afina W Lemstra, Bart N M van Berckel, Andrea Pilotto, Alessandro Padovani, Miguel A Ochoa-Figueroa, Anette Davidsson, Valle Camacho, Enrico Peira, Matteo Bauckneht, Matteo Pardini, Gianmario Sambuceti, Dag Aarsland, Flavio Nobili, Mattes Gross, Jonathan Vöglein, Robert Perneczky, Oliver Pogarell, Katharina Buerger, Nicolai Franzmeier, Adrian Danek, Johannes Levin, Günter U Höglinger, Peter Bartenstein, Paul Cumming, Axel Rominger, Matthias Brendel
PURPOSE: Metabolic network analysis of FDG-PET utilizes an index of inter-regional correlation of resting state glucose metabolism and has been proven to provide complementary information regarding the disease process in parkinsonian syndromes. The goals of this study were (i) to evaluate pattern similarities of glucose metabolism and network connectivity in dementia with Lewy bodies (DLB) subjects with subthreshold dopaminergic loss compared to advanced disease stages and to (ii) investigate metabolic network alterations of FDG-PET for discrimination of patients with early DLB from other neurodegenerative disorders (Alzheimer's disease, Parkinson's disease, multiple system atrophy) at individual patient level via principal component analysis (PCA)...
November 16, 2023: European Journal of Nuclear Medicine and Molecular Imaging
https://read.qxmd.com/read/37962393/hippocampal-perfusion-affects-motor-and-cognitive-functions-in-parkinson-disease-an-early-phase-18-f-fp-cit-positron-emission-tomography-study
#30
JOURNAL ARTICLE
Min Young Chun, Seok Jong Chung, Su Hong Kim, Chan Wook Park, Seong Ho Jeong, Hye Sun Lee, Phil Hyu Lee, Young H Sohn, Yong Jeong, Yun Joong Kim
OBJECTIVE: We investigated whether hippocampal perfusion changes are associated with cognitive decline, motor deficits, and the risk of dementia conversion in patients with Parkinson disease (PD). METHODS: We recruited patients with newly diagnosed and nonmedicated PD and healthy participants who underwent dual phase 18 F-N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl) nortropane positron emission tomography scans. Patients were classified into 3 groups according to hippocampal perfusion measured by standard uptake value ratios (SUVRs): (1) PD hippocampal hypoperfusion group (1 standard deviation [SD] below the mean hippocampal SUVR of healthy controls; PD-hippo-hypo), (2) PD hippocampal hyperperfusion group (1 SD above the mean; PD-hippo-hyper), and (3) the remaining patients (PD-hippo-normal)...
November 14, 2023: Annals of Neurology
https://read.qxmd.com/read/37958780/receptor-independent-therapies-for-forensic-detainees-with-schizophrenia-dementia-comorbidity
#31
JOURNAL ARTICLE
Adonis Sfera, Luminita Andronescu, William G Britt, Kiera Himsl, Carolina Klein, Leah Rahman, Zisis Kozlakidis
Forensic institutions throughout the world house patients with severe psychiatric illness and history of criminal violations. Improved medical care, hygiene, psychiatric treatment, and nutrition led to an unmatched longevity in this population, which previously lived, on average, 15 to 20 years shorter than the public at large. On the other hand, longevity has contributed to increased prevalence of age-related diseases, including neurodegenerative disorders, which complicate clinical management, increasing healthcare expenditures...
October 31, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/37883190/cardiac-noradrenergic-deficiency-revealed-by-18f-dopamine-positron-emission-tomography-identifies-preclinical-central-lewy-body-diseases
#32
JOURNAL ARTICLE
David S Goldstein, Courtney Holmes, Patti Sullivan, Grisel Lopez, Janna Gelsomino, Sarah Moore, Risa Isonaka, Tianxia Wu, Yehonatan Sharabi
BACKGROUND: In Lewy body diseases (LBDs) Parkinson disease (PD), and dementia with Lewy bodies (DLB), by the time parkinsonism or cognitive dysfunction manifests clinically, substantial neurodegeneration has already occurred. Biomarkers are needed to identify central LBDs in a preclinical phase, when neurorescue strategies might forestall symptomatic disease. This phase may involve catecholamine deficiency in the autonomic nervous system. We analyzed data from the prospective, observational, long-term PDRisk study to assess the predictive value of low versus normal cardiac 18F-dopamine positron emission tomography (PET), an index of myocardial content of the sympathetic neurotransmitter norepinephrine, in at-risk individuals...
January 2, 2024: Journal of Clinical Investigation
https://read.qxmd.com/read/37843677/cardiac-18-f-dopamine-positron-emission-tomography-predicts-the-type-of-phenoconversion-of-pure-autonomic-failure
#33
JOURNAL ARTICLE
Abhishek Lenka, Risa Isonaka, Courtney Holmes, David S Goldstein
PURPOSE: Pure autonomic failure (PAF) is a rare disease characterized by neurogenic orthostatic hypotension (nOH), no known secondary cause, and lack of a neurodegenerative movement or cognitive disorder. Clinically diagnosed PAF can evolve ("phenoconvert") to a central Lewy body disease [LBD, e.g., Parkinson's disease (PD) or dementia with Lewy bodies (DLB)] or to the non-LBD synucleinopathy multiple system atrophy (MSA). Since cardiac 18 F-dopamine-derived radioactivity usually is low in LBDs and usually is normal in MSA, we hypothesized that patients with PAF with low cardiac 18 F-dopamine-derived radioactivity would be more likely to phenoconvert to a central LBD than to MSA...
October 16, 2023: Clinical Autonomic Research: Official Journal of the Clinical Autonomic Research Society
https://read.qxmd.com/read/37843383/review-of-dopamine-antagonists-for-nausea-and-vomiting-in-palliative-care-patients
#34
REVIEW
Grace Jenkins
Symptoms of nausea and vomiting are common in palliative care and hospice patients. One of the many classes of medications used for the treatment of nausea and vomiting is dopamine receptor antagonists which are particularly helpful for treating nausea mediated by the chemoreceptor trigger zone (CTZ) and impaired gastrointestinal function. While dopamine antagonists can be very effective treatments for nausea they should be used with caution as they carry the risk of QTc prolongation, have a FDA black box warning for tardive dyskinesia (TD), and increased risk of precipitating psychosis and death in patients with dementia...
October 16, 2023: Journal of Pain & Palliative Care Pharmacotherapy
https://read.qxmd.com/read/37833807/mesenchymal-stromal-cell-biotherapy-for-parkinson-s-disease-premotor-symptoms
#35
REVIEW
Jinmei Sun, Wei Zhang, Zheng Zachory Wei, Xiaopeng Song, Liu Jian, Feng Jiang, Shuanglin Wang, Haibo Li, Yongbo Zhang, Houzhen Tuo
Parkinson's disease (PD) is a neurodegenerative disorder with motor deficits due to nigrostriatal dopamine depletion and with the non-motor/premotor symptoms (NMS) such as anxiety, cognitive dysfunction, depression, hyposmia, and sleep disorders. NMS is presented in at least one-fifth of the patients with PD. With the histological information being investigated, stem cells are shown to provide neurotrophic supports and cellular replacement in the damaging brain areas under PD conditions. Pathological change of progressive PD includes degeneration and loss of dopaminergic neurons in the substantia nigra of the midbrain...
October 13, 2023: Chinese Neurosurgical Journal
https://read.qxmd.com/read/37811009/parkinson-s-disease-updates-addressing-the-pathophysiology-risk-factors-genetics-diagnosis-along-with-the-medical-and-surgical-treatment
#36
REVIEW
Priyadarshi Prajjwal, Herson S Flores Sanga, Kirtish Acharya, Tamara Tango, Jobby John, Rene S C Rodriguez, Mohammed Dheyaa Marsool Marsool, Mukhamed Sulaimanov, Aneeqa Ahmed, Omniat A Hussin
After only Alzheimer's disease (AD), Parkinson's disease (PD) is the second most prevalent neurodegenerative disease. The incidence of this disease increases with age, especially for those above 70 years old. There are many risk factors that are well-established in the contribution to the development of PD, such as age, gender, ethnicity, rapid eye movement sleep disorder, high consumption of dairy products, traumatic brain injury, genetics, and pesticides/herbicides. Interestingly, smoking, consumption of caffeine, and physical activities are the protective factors of PD...
October 2023: Annals of Medicine and Surgery
https://read.qxmd.com/read/37726343/cortical-lewy-body-injections-induce-long-distance-pathogenic-alterations-in-the-non-human-primate-brain
#37
JOURNAL ARTICLE
Margaux Teil, Sandra Dovero, Mathieu Bourdenx, Marie-Laure Arotcarena, Morgane Darricau, Gregory Porras, Marie-Laure Thiolat, Inés Trigo-Damas, Celine Perier, Cristina Estrada, Nuria Garcia-Carrillo, María Trinidad Herrero, Miquel Vila, José A Obeso, Erwan Bezard, Benjamin Dehay
Aggregation of α-synuclein (α-syn) is the cornerstone of neurodegenerative diseases termed synucleinopathies, which include Parkinson's Disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA). These synucleinopathies are characterized by the deposit of aggregated α-syn in intracellular inclusions observable in neurons and glial cells. In PD and DLB, these aggregates, predominantly located in neurons, are called Lewy Bodies (LBs). These LBs are one of the pathological hallmarks of PD and DLB, alongside dopaminergic neuron loss in the substantia nigra...
September 19, 2023: NPJ Parkinson's Disease
https://read.qxmd.com/read/37726104/association-between-longitudinal-changes-in-striatal-dopamine-transporter-uptake-and-clinical-features-of-dementia-with-lewy-bodies
#38
JOURNAL ARTICLE
Ryo Yamamoto, Naoto Takenoshita, Yuta Inagawa, Hikaru Kato, Kyoko Kaneshiro, Tomoki Kamiya, Shoya Inagawa, Aya Saisho, Akito Tsugawa, Yukari Mastumoto, Mana Yoshimura, Kazuhiro Saito, Soichiro Shimizu, Tomohiko Sato
BACKGROUND: It is widely known that there is low striatal 123 I-2β-Carbomethoxy-3β-(4-iodophenyl)-N-(3- fluoropropyl) nortropane (123 I-FP-CIT) dopamine transporter single photon emission tomography (DaT-SPECT) uptake in patients with dementia with Lewy bodies (DLB). No studies to date have analyzed the association between longitudinal changes of clinical features and DaT uptake in patients with Parkinson syndrome, particularly those with DLB. The aim of this study was to investigate the association between the longitudinal changes in DaT uptake and the severity of parkinsonism and cognitive function in DLB patients...
September 19, 2023: Psychogeriatrics: the Official Journal of the Japanese Psychogeriatric Society
https://read.qxmd.com/read/37724196/delayed-presentation-of-antipsychotic-withdrawal-tardive-dyskinesia-a-case-report
#39
Siddhant Solanki, Lakshmi Sai Deepak Reddy Velugoti
Tardive dyskinesia (TD) is an iatrogenic cause that occurs after prolonged use of antipsychotic and other dopamine-related medications and is described as repetitive, involuntary movement of muscles in the body. This case report focuses on an 80-year-old man who presented with a medical history encompassing dementia, bilateral blindness, glaucoma, hearing loss, hypertension, and hypercholesterolemia. He visited the clinic with a complaint of experiencing visual hallucinations. Investigations, including a CT head and EEG, revealed normal results, and Risperidone was prescribed...
August 2023: Curēus
https://read.qxmd.com/read/37723871/side-effects-based-network-construction-and-drug-repositioning-of-ropinirole-as-a-potential-molecule-for-alzheimer-s-disease-an-in-silico-in-vitro-and-in-vivo-study
#40
JOURNAL ARTICLE
Amritha Chakkittukandiyil, Saurav Chakraborty, Ram Kothandan, Emdormi Rymbai, Santhosh Kumar Muthu, Soumya Vasu, Deepak Vasudevan Sajini, Deepa Sugumar, Zubair Baba Mohammad, Saravanan Jayaram, Kalirajan Rajagopal, Vadivelan Ramachandran, Divakar Selvaraj
Alzheimer's disease (AD) is the leading cause of dementia in older adults. Drug repositioning is a process of finding new therapeutic applications for existing drugs. One of the methods in drug repositioning is to use the side-effect profile of a drug to identify a new therapeutic indication. The drugs with similar side-effects may act on similar biological targets and could affect the same biochemical process. In this study, we explored the Food and Drug Administration-approved drugs using PROMISCUOUS database to find those that have adverse effects profile comparable with the ligands being studied or used to treat AD...
September 18, 2023: Journal of Biomolecular Structure & Dynamics
keyword
keyword
162597
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.